

## February 26, 2021

Canadian Pioneer Medical Technology Corporation Dr. Rashid Reza Mir Sayah Managing Director Unit 2, 210 Drumlin Circle Concord, Vaughan, Ontario L4K 3E3 CAN

Re: K210033

Trade/Device Name: Laser Treatment System, Model: NYX and Grace

Regulation Number: 21 CFR 878.4810

Regulation Name: Laser Surgical Instrument For Use In General And Plastic Surgery And In

Dermatology

Regulatory Class: Class II

Product Code: GEX

Dated: December 24, 2020 Received: January 5, 2021

## Dear Dr. Rashid Reza Mir Sayah:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm</a> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <a href="https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products">https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products</a>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <a href="https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems">https://www.fda.gov/medical-device-problems</a>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance</a>) and CDRH Learn (<a href="https://www.fda.gov/training-and-continuing-education/cdrh-learn">https://www.fda.gov/training-and-continuing-education/cdrh-learn</a>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<a href="https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</a>) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Purva Pandya
Assistant Director
DHT4A: Division of General Surgery Devices
OHT4: Office of Surgical and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

# DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

## **Indications for Use**

510(k) Number (if known)

K210033

Form Approved: OMB No. 0910-0120

Expiration Date: 06/30/2020 See PRA Statement below.

<b>K</b> 210033		
Device Name		
Laser Treatment System, Model: NYX and Grace		
Indications for Use (Describe)		
The Laser Treatment System is intended for hair removal, perman	nent hair reduction on all skin types (Fitzpatrick	
skin type I-VI), including tanned skin. Permanent hair reduction is defined as the long-term, stable reduc	ction in the number of hairs regrowing when measured at	
6, 9, and 12 months after the completion of a treatment regime.	when measured at	
, ,		
Type of Use (Select one or both, as applicable)		
	Over-The-Counter Use (21 CFR 801 Subpart C)	
CONTINUE ON A SERVICE		
CONTINUE ON A SEPARATE PAGE IF NEEDED.		

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

# 510(k) Summary: K210033

#### I. Submitter

Canadian Pioneer Medical Technology Corporation
Unit 2-210 Drumlin Circle, Vaughan, Ontario, L4K 3E3, Canada

Contact person:

Dr. Rashid Reza Mir Sayah

Managing Director Phone: 4377727788

Email:

Canadianpioneer@yahoo.com Canadianpioneer@gmail.com Info@Canadianlasers.com

Date of preparation: Feb.20<sup>th</sup>, 2021

#### **II. Subject Device**

Trade Name of Device: Laser Treatment System, Model: NYX and Grace

Common name: Powered Laser Surgical Instrument

Classification Name: Laser Surgical Instrument For Use In General And Plastic Surgery

And In Dermatology

Regulation Number: 21 CFR 878.4810

Regulatory Class: II Product code: GEX

Review Panel: General & Plastic Surgery

#### **III. Predicate Devices**

Trade Name of Device: Diode Laser Treatment System Manufacturer: Weifang KM Electronics Co., LTD"

Common name: Powered Laser Surgical Instrument

Regulation Number: 21 CFR 878.4810

Regulatory Class: II Product code: GEX

Review Panel: General & Plastic Surgery

510(k) number: K182924

#### IV. Device description

The Laser Treatment System consists of the main unit and a hand piece. The system uses a diode laser as an active medium placed in an optical cavity to produce amplified

beam at the wavelength of 808 nm. A microprocessor is used to control electronics for the front panel. A self-contained water cooling system is built into the power supply unit. The diode laser operates in a pulsed mode with a fixed pulse width and fixed pulse duration of the pulse train for each mode. The number of pulses can be adjusted within the preset range.

The Laser Treatment System includes two (2) models, NYX and Grace, the differences between them are the external shape and the numbers of the handpiece connectors, NYX is the desktop type with one handpiece connector, and Grace is vertical stand type with two handpiece connectors.

#### V. Indications for use

The Laser Treatment System is intended for hair removal, permanent hair reduction on all skin types (Fitzpatrick skin type I-VI), including tanned skin.

Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs regrowing when measured at 6, 9, and 12 months after the completion of a treatment regime.

# VI. Comparison of technological characteristics with the predicate devices

The Laser Treatment System has the same technological characteristics and fundamental design as the predicate device. The subject device and the predicate devices are all designed for hair removal on different parts of the body. The differences between the subject device and predicate devices do not alter suitability of the proposed device for its intended use.

Device feature	Laser Treatment System, Model:	Diode Laser Treatment System
	NYX and Grace (K210033)	(K182924)
Manufacturer	Canadian Pioneer Medical	Weifang KM Electronics Co., Ltd.
	Technology Corporation	
Product code	GEX	GEX
Regulation	21 CFR 878.4810	21 CFR 878.4810
number		
Indications for	The Laser Treatment System is	The Diode Laser Treatment System
use	intended for hair removal,	is intended for hair removal,
	permanent hair reduction on all skin	permanent hair reduction on all skin
	types (Fitzpatrick skin type I-VI),	types (Fitzpatrick skin type I-VI),
	including tanned skin. Permanent	including tanned skin. □Permanent
	hair reduction is defined as the	hair reduction is defined as the
	long-term, stable reduction in the	long-term, stable reduction in the
	number of hairs regrowing when	number of hairs regrowing when
	measured at 6, 9, and 12 months	measured at 6, 9, and 12 months
	after the completion of a treatment	after the completion of a treatment

	regime.	regime.
Operation	Melanin could absorb the energy	Melanin could absorb the energy
principle	from the laser, which would result in	from the laser, which would result in
	temperature rapid increase, to	temperature rapid increase, to
	destroy surrounding hair follicles,	destroy surrounding hair follicles,
	and finally remove hair.	and finally remove hair.
Laser type	Diode laser	Diode laser
Laser	Class IV	Class IV
classification		
Laser	808nm	808nm
wavelength		
Spot Size	1.44 cm <sup>2</sup>	1.44 cm <sup>2</sup>
Fluence	1-120J/cm <sup>2</sup>	2-120J/cm <sup>2</sup>
Frequency	1-10Hz	1-10Hz
Pulse Duration	10-300ms	10-300ms
Power supply	100-240V AC, 50/60Hz	100-240V AC, 50/60Hz
Patient contact	Sapphire in handpiece and	Sapphire in handpiece and
material	handpiece tip (stainless steel)	handpiece tip (stainless steel)
Biocompatibility	Comply with ISO10993-1	Comply with ISO10993-1
Electrical	Comply with IEC60601-1,	Comply with IEC60601-1,
Safety	IEC60601-2-22	IEC60601-2-22
EMC	Comply with IEC 60601-1-2,	Comply with IEC60601-1-2,
Laser safety	Comply with IEC60825-1,	Comply with IEC60825-1,
	IEC60601-2-22	IEC60601-2-22

## **VII Summary of Non-clinical Performance Testing**

The following performance data were provided in support of the substantial equivalence determination.

## **Biocompatibility testing**

Biocompatibility of the Laser Treatment System was evaluated in accordance with ISO 10993-1:2009 for the body contact category of "Surface –intact skin" with a contact duration of "Limited (< 24 hours)". The following tests were performed, as recommended: Cytotoxicity, Irritation and Sensitization. All evaluation acceptance criteria were met

## Electrical safety and electromagnetic compatibility (EMC)

Electrical safety and EMC testing were conducted on the Laser Treatment System. The system has been tested to comply with the following standards:

 IEC 60601-1:2012 Medical Electrical Equipment - Part 1: General Requirements For Basic Safety And Essential Performance;  IEC 60601-1-2:2014, Medical electrical equipment- Part 1-2: General requirements for basic safety and essential performance- Collateral standard: Electromagnetic compatibility- Requirements and tests.

# **Bench Testing**

- IEC 60601-2-22:2007 + A1:2012, Medical Electrical Equipment Part 2-22: Particular Requirements For Basic Safety And Essential Performance Of Surgical, Cosmetic, Therapeutic And Diagnostic Laser Equipment;
- IEC 60825-1: 2007, Safety of laser products Part 1: Equipment classification and requirements.

## Software Validation and Verification Testing

The Laser Treatment System also underwent software verification and validation, with results demonstrating that the software is appropriate for release. System verification testing further confirmed that the system performs as intended, and that the energy outputs of the device meet specifications.

#### **VIII Conclusion**

The non-clinical testing demonstrates that the device is as safe, as effective and performs as well as the legally marketed device (K182924).